Today, the innovators of drug discovery and development are the smaller biotech and biopharma companies around the world. According to a report from HBM Partners AG, in the past several years, more than 60% of new drugs approved originated at small and midsize companies – those outside the 30 largest pharmaceutical firms.
This article is taken from PharmaVoice, April 2017, by Peter Benton.
Authors:
Peter Benton, MBA
President and Chief Executive Officer
